Editorial abstract cover illustrating Diabetes Market Research in the UAE After the 2026 Price Cuts
    Market Research

    A list-price cut is not a change in prescriptions — Diabetes market research UAE after the 2026 price cuts

    M
    Martha DeVitoGlobal Research Manager
    17 Oct 2026
    10 min
    United Arab Emirates
    Diabetes Market Research UAEEmirates Drug EstablishmentUAE Drug PricingType 2 DiabetesMarket AccessPrimary ResearchUnited Arab EmiratesPharmaceutical Pricing
    Share:

    Diabetes market research UAE after the 2026 price cuts is commissioned work on named packs, not a prevalence slide. Read it with the healthcare market research hub. The federal handover sits on the EDE takeover briefing.

    What this study is

    It asks which named pack moved, who still writes it, what the pharmacy did, and which wallet pays. Grand View Research, IMARC and IQVIA sell national outlooks. They do not name the pack or the payer. See diabetes market research in the UAE.

    Timeline of Emirates Drug Establishment dates a UAE diabetes brief must keep separate in 2026
    Dates a diabetes market research UAE file must split: Decree-Law 28/2023, Decree-Law 38/2024 in force 2 January 2025, MOHAP’s 44-service transfer on 5 January 2026, and Decision 12/2026.

    What Decision 12 cut in diabetes

    Gulf News, writing on 26 May 2026, reported that the Emirates Drug Establishment cut retail prices of 168 products used for chronic disease. The published range was about 5% to nearly 60%. The named diabetes examples were Amaryl 1 mg, from AED 25 to AED 19; Amaryl 2 mg, from AED 39.50 to AED 32; and Amaryl 3 mg, from AED 57.50 to AED 47.50 (Gulf News).

    Amaryl is the originator glimepiride tablet (FDA Amaryl label). Gulf News described the diabetes group as glipizide, alone or with metformin, and then listed those three Amaryl strengths. That molecule wording is not a confirmed glipizide cut. The confirmed facts are the brand, the three strengths and the three dirham pairs.

    The same report’s cholesterol and glaucoma examples are not diabetes cuts. Zocor 40 mg fell about 59.5%. Xalatan fell about 51.7% (Gulf News). Do not load those cuts into a diabetes profit-and-loss.

    Gulf News, on 26 May 2026, said pharmacies were already showing new prices, and that the cut would take effect on 30 May 2026 (Gulf News). A legal listing records issuance on 22 April 2026, Official Gazette No. 822 on 30 April 2026, and entry into force on 12 June 2026 (Eastlaws). Keep both dates. Do not collapse them.

    Illustration that Gulf News published separate examples from the 2026 price list, including Amaryl
    Gulf News, 26 May 2026, is the source for dirham pairs on Amaryl 1 mg, 2 mg and 3 mg, and for cuts of about 59.5 percent on Zocor 40 mg and about 51.7 percent on Xalatan. Do not turn those examples into one diabetes-class cut.

    A prevalence is not a treated share

    The IDF Atlas, 11th edition, puts 1,274.2 thousand adults aged 20–79 with diabetes in 2024, an age-standardised prevalence of 20.7%, and an undiagnosed share of 64.0% (815.5 thousand). The same table records 768.0 thousand and 18.8% in 2011, and a 2050 projection of 1,876.5 thousand and 22.7% (IDF Atlas). Those are modelled estimates, not a count of patients on one class.

    MOHAP’s 2017–2018 survey of 10,000 families, with a 94% response, put adult diabetes at 11.8%, down from 18.9% in 2010 (MOHAP NHS; UNDP). The 2024–2025 nutrition survey reported elevated blood glucose of 12.5%, obesity of 22.4%, high blood pressure of 25.9% and high cholesterol of 54.2% (MOHAP NHNS). Do not average 20.7%, 11.8% and 12.5%.

    Gulf News, on the same 9,997-household survey, wrote that 18.3% of adults had never had blood sugar tested, and that 90.4% of those diagnosed had taken medication in the previous two weeks. Private outpatient visits were 67.8%, against 31.9% in government (Gulf News). That medication line is a survey answer. It is not national demand for one pack.

    Dubai household surveys are not a national treated share. The 2014 and 2017 rounds found diabetes of 19% among nationals, 14.7% among expatriates and 15.2% overall (Alawadi et al.). The 2019 survey of 9,630 adults in 2,496 households found total diabetes of 13.7% (11.5% known, 2.1% newly diagnosed), 19.3% among Emiratis and 12.4% among expatriates (Al Awadi et al.).

    FCSC puts the 2024 population at 11.29 million, up 5.7% from 10.68 million (FCSC). Do not apply 20.7% or 11.8% to 11.29 million and call the result demand for Amaryl.

    Comparison of published UAE diabetes prevalence methods that a launch model must not average
    Four methods, not one count: IDF 20.7% (20–79, 2024); MOHAP NHS 11.8% (adults 18+, 2017–18); NHNS 12.5% elevated glucose (2024–25); Dubai 2019 19.3% Emirati versus 12.4% expatriate.

    What changes on price

    Article 20 of Federal Decree-Law No. 38 of 2024 requires a Board-set price before marketing. Article 22 requires at least two licensed importers (Article 20 and Article 22). The law took effect on 2 January 2025, with a one-year grace (UAE Legislation; Baker McKenzie).

    Federal Decree-Law No. 28 of 2023 was issued on 25 September 2023 and took effect on 30 September 2023 (UAE Legislation; Lexis). On 5 January 2026, MOHAP transferred 44 services, including re-pricing and price lists (MOHAP; MOHAP service list). The portal says the Establishment was founded on 29 September (EDE portal). That is not the decree date.

    Decision 140 of 2013 still sits in the mark-up path Chambers describes: import price plus 15%, then 28%, 24% or 20% by band. Cabinet Decision 90 of 2021 bars unauthorised discounts (Chambers). Decision 49 of 2025 still recites Decision 140/2013 (Decision 49/2025). Re-pricing fees are AED 1,000 plus AED 500 (EDE re-pricing).

    WAM’s first-half note, to 30 June 2026, counts 942 approvals, 20 pricing decisions and 2,030 inspection visits. It also reports a multi-importer mechanism in February 2026 (WAM). Decision 12 is one of those 20 pricing decisions. It is not a class-wide analog cut.

    Foundayo (orforglipron) was approved on 3 April 2026 for weight management, expected from May 2026, with 12.4% mean trial weight loss (WAM, 3 April 2026). That is not a Decision 12 diabetes price. See the oral GLP-1 UAE market research brief. Inpefa (sotagliflozin), named in the same half-year note, is not a Decision 12 diabetes price either (WAM). Decision No. 47 of 2025 adopted the national essential-medicines list (EDE legislations; Decision 47/2025; WHO).

    How physicians and pharmacies may respond

    DHA’s virtual Type 2 guideline, CG-41 Issue 2, is dated 21 February 2024 and took effect on 21 April 2024. It still treats drug treatment as a clinical sequence (DHA CG-41). A lower Amaryl list price does not publish a switch to another class. Anonymous diaries, new versus continuing, are how a team finds out what prescribers did.

    Ask pharmacies separately. Cabinet Decision 90 of 2021 bars unauthorised discounts (Chambers). The Dubai code already carries a price field (GC 12/2018). A federal cut and a code update are two changes. EnterpriseAM reported on 6 January 2026 that narcotics stay with the ministry (EnterpriseAM).

    Three UAE diabetes access layers after the 2026 list cut: federal price, emirate listing and wallet
    Three layers after Decision 12: the federal list price EDE now sets; DHA, DOH and insurer listing, including Thiqa enrolment; and the wallet that funds the script.

    A list cut is not a payer listing

    Dubai Law No. 11 of 2013 makes cover mandatory, including free zones such as DIFC (Law 11/2013; Dubai.ae). The UNDP case describes Thiqa for Abu Dhabi nationals, Saada in Dubai, and employer cover for expatriates (UNDP). A public price can still sit outside a basic plan.

    DoH Circular 188 of 2025 launched a Thiqa diabetes programme for adults 18 and older, with two outpatient visits and HbA1c of 6.5% or higher, as 12 months of coordinated care (Circular 188/2025). That is an enrolment pathway. It is not a decision to list or drop Amaryl after Decision 12.

    What the study should measure

    Keep the named dirham pairs, the treated-patient share, the prescriber, the pharmacy and the payer on separate rows.

    WorkstreamDecision it answersWhat the published record already showsWhat to commission
    Analog mapWhich diabetes SKU actually movedDecision 12 named 168 products; the published diabetes examples are Amaryl 1 mg, 2 mg and 3 mg (Gulf News, 26 May 2026)Dose-level map of named SKUs; do not fill gaps with unpublished GLP-1 or SGLT2 rows
    Treated-patient shareWhat happens after the cutDubai 2019 total diabetes was 13.7%, of which 11.5% known and 2.1% newly diagnosed (Al Awadi et al., 2020)Anonymous PRFs, new versus continuing, by class and emirate
    Physician switchingWhether intensification changedDHA’s 2024 telehealth Type 2 guideline still walks initiating and re-prescribing drug treatment as a clinical sequence (DHA CG-41)Endocrinologist, internist and GP interviews in Dubai, Abu Dhabi and at least one northern emirate
    Pharmacy behaviourWhat the counter didCabinet Decision 90/2021 bars unauthorised discounts; DDC codes already carry a price field (Chambers; GC 12/2018)Community and hospital pharmacy interviews on stock, substitution and co-pay
    Payer listingWho funds the scriptDoH launched a Thiqa diabetes disease-management pilot for adults 18+ with two outpatient visits and HbA1c ≥6.5% (DoH Circular 188/2025)Separate DHA, DOH and insurer interviews — see UAE pricing and reimbursement strategy
    Checklist of seven diabetes market research UAE workstreams after the 2026 price cuts
    Seven diabetes market research UAE workstreams after Decision 12: analog map, treated share, switching, pharmacy, payer listing, budget impact, and oral GLP-1 as a separate brief.

    Do not fill unpublished GLP-1, SGLT2, DPP-4 or insulin cuts into the Decision 12 row. Do not price a GLP-1 invoice against an Amaryl pair and call it one class effect.

    How to commission the study

    Name the three Amaryl strengths, the date you are using for “in force,” and the emirates in the sample. Field physicians in Dubai, Abu Dhabi and at least one northern emirate. Separate DHA, Department of Health and insurer interviews. See UAE pricing and reimbursement strategy.

    How to brief BioNixus

    BioNixus is a primary market research firm for pharmaceutical, medical device and healthcare companies. It was founded in 2012. It has served 118 clients in 48 countries. It has run 127 studies so far in 2026. It works with a network of 82,000+ physicians globally and about 3,200 physicians in the Middle East. Custom studies are usually priced at $10k–$60k. Leadership offices are in Sheridan, Wyoming, London EC1V 2NX, and Sheikh Zayed, Giza. There are a field office for UAE in Dubai, a partner office for KSA in Al Khobar, and a field office for Kuwait in Salmiya. São Paulo is a field office for LATAM. Work in Latin America is covered today from the US office with local consultants.

    The line “Guaranteed in writing” covers scope, timing, replacement of respondents who do not qualify, the minimum sample, re-fielding if that sample is missed, and a credited pilot. It does not cover what the interviews will find. BioNixus has 40 client reviews.

    Use the contact form or email admin@bionixus.com.

    References

    1. Gulf News (Abdulla Rasheed). UAE cuts prices of 168 medicines for chronic diseases by up to 60 per cent. 26 May 2026. Decision 12/2026; Amaryl 1/2/3 mg AED pairs; Zocor ~59.5%; Xalatan ~51.7%. Source (accessed 17 October 2026).
    2. Eastlaws. Decision of the Chairman of the Board of the Emirates Drug Establishment No. 12 | 2026. Issued 22 April 2026; Official Gazette No. 822, 30 April 2026; in force 12 June 2026. Source (accessed 17 October 2026).
    3. MOHAP. Ministry of Health and Prevention transfer key services to Emirates Drug Establishment. 5 January 2026. 44 core services, including individual-product re-pricing and price-list publication. Source (accessed 17 October 2026).
    4. MOHAP. Transfer of services to the Emirates Drug Establishment (service list). Directs transferred-category applications to the EDE portal. Source (accessed 17 October 2026).
    5. UAE Legislation. Federal Decree-Law No. 28 of 2023 on the UAE Drug Corporation. Issued 25 September 2023; Gazette 29 September 2023, No. 760; effective 30 September 2023. Source (accessed 17 October 2026).
    6. Lexis Middle East. Federal Decree-Law No. 28/2023 On the Establishment of the UAE Drug Corporation. Issued 25 September 2023. Source (accessed 17 October 2026).
    7. UAE Legislation. Federal Decree-Law No. 38 of 2024 Governing Medical Products, Pharmacists and Pharmaceutical Establishments. Issued 1 October 2024; effective 2 January 2025. Source (accessed 17 October 2026).
    8. FAOLEX English text. Federal Decree-Law No. (38) of 2024. Article 20 (Board pricing); Article 22 (at least two licensed importers); Article 7 (five-year marketing approval). Source (accessed 17 October 2026).
    9. Baker McKenzie. UAE: Enacts New Medical Products Law. 14 January 2025. In force 2 January 2025, with a one-year grace period, to facilitate EDE’s take-over from MOHAP. Source (accessed 17 October 2026).
    10. WAM. Emirates Drug Establishment boosts pharmaceutical readiness in H1 2026. 22 September 2026. To 30 June: 2,030 visits; 20 pricing decisions; 942 approvals. Names Foundayo and Inpefa. Source (accessed 17 October 2026).
    11. WAM. Emirates Drug Establishment approves new oral obesity treatment. 3 April 2026. Foundayo (orforglipron) for chronic weight management; expected availability from May 2026; 12.4% mean trial weight loss. Source (accessed 17 October 2026).
    12. Emirates Drug Establishment. Re-Pricing of a Single Medical Product. Country-of-origin certificate, justifications, Gulf plus European references; AED 1,000 plus AED 500 for a new certificate. Source (accessed 17 October 2026).
    13. Emirates Drug Establishment. Legislations. Decree-Law 28/2023 (25 September 2023) and Chairman Decision 47/2025 adopting the NEML (19 June 2025). Source (accessed 17 October 2026).
    14. Chambers, Life Sciences 2026 (UAE). EDE sets prices; Cabinet Decision 90/2021 bars unauthorised discounts; Decision 140/2013 CIF mark-ups +15% then +28/24/20%. Source (accessed 17 October 2026).
    15. realLaw AI. EDE Chairman Decision No. 49 of 2025 on pricing of certain medical products. Recital still cites Ministerial Decision 140/2013. Source (accessed 17 October 2026).
    16. U.S. FDA. AMARYL (glimepiride) tablets prescribing information. Identifies Amaryl as originator glimepiride; not a UAE label or price. Source (accessed 17 October 2026).
    17. IDF Diabetes Atlas, 11th edition, United Arab Emirates. 2024 adults 20–79: 1,274.2 thousand; age-standardised prevalence 20.7%; undiagnosed 64.0%. 2011: 768.0 thousand / 18.8%. 2050: 1,876.5 thousand / 22.7%. Source (accessed 17 October 2026).
    18. MOHAP. National Health Survey results. 2017–2018; 10,000 families, 94% response. Diabetes among adults 18+ (high glucose or diabetes medication) 11.8%, from 18.9% in 2010. Source (accessed 17 October 2026).
    19. MOHAP. National Health and Nutrition Survey 2024–2025, adults 18+: obesity 22.4%; high blood pressure 25.9%; elevated blood glucose 12.5%; high cholesterol 54.2%. Source (accessed 17 October 2026).
    20. Gulf News (Huda Ata). High cholesterol affects more than half of UAE adults. 17 October 2026. NHNS 2024–2025 (9,997 households): 12.5% elevated glucose; 18.3% never tested; 90.4% of diagnosed taking medication; private OP 67.8%. Source (accessed 17 October 2026).
    21. Alawadi F, et al. Dubai Household Health Surveys 2014 and 2017. Dubai Diabetes Endocrinol J. 2020;26(2):78–86. Diabetes 19% nationals, 14.7% expatriates, 15.2% overall (HbA1c). Source (accessed 17 October 2026).
    22. Al Awadi F, et al. Dubai Household Survey 2019. Dubai Diabetes Endocrinol J. 2020;26(4):164–173. 9,630 adults: total diabetes 13.7%; Emirati 19.3% versus expatriate 12.4%. Source (accessed 17 October 2026).
    23. FCSC. Unified UAE Numbers (English), December 2025. Population about 11.29 million in 2024, up 5.7% from 10.68 million in 2023. Source (accessed 17 October 2026).
    24. Department of Health — Abu Dhabi. Circular 188/2025, Diabetes Disease Management Program. Thiqa adults 18+ with two diabetes outpatient visits and HbA1c ≥6.5%; 12-month coordinated care. Source (accessed 17 October 2026).
    25. Dubai Health Authority. Clinical Guidelines for Virtual Management of Type 2 Diabetes Mellitus, DHA/HRS/HPSD/CG-41 Issue 2. 21 February 2024; effective 21 April 2024. Source (accessed 17 October 2026).
    26. Government of Dubai. Law No. (11) of 2013 Concerning Health Insurance in the Emirate of Dubai, including special development zones and DIFC. Source (accessed 17 October 2026).
    27. Dubai.ae. Health Insurance. Law 11/2013 makes cover mandatory; Dubai employers, including free zones, must insure employees; sponsors cover dependents. Source (accessed 17 October 2026).
    28. UNDP / Gulf Health Council. UAE NCD investment case. 2017–2018 STEPS diabetes 11.8% (adults 18+); Thiqa (Abu Dhabi nationals); Saada (Dubai); employer cover in both emirates. Source (accessed 17 October 2026).
    29. DHA / ISAHD. eClaimLink GC 12/2018, Dubai Drug Code List. Each registered drug carries a DDC code including pack size, price, manufacturer and source. Source (accessed 17 October 2026).
    30. WHO. United Arab Emirates: National Essential Medicine List 2025 (English). Repository date 3 June 2026. Source (accessed 17 October 2026).
    31. DHA-hosted EDE Chairman Decision No. (47) of 2025 adopting the NEML, signed 19 June 2025 by Dr Thani Ahmed Al Zeyoudi. Source (accessed 17 October 2026).
    32. EnterpriseAM UAE. Health Ministry transfers licensing and medicines registration to EDE. 6 January 2026. Narcotics and some high-sensitivity controlled substances remain with the ministry. Source (accessed 17 October 2026).
    33. Emirates Drug Establishment portal. Search copy states the Establishment was founded on 29 September. Published contacts: 800 33784 and info@ede.gov.ae. Source (accessed 17 October 2026).
    34. Grand View Research. UAE antidiabetics and pharmaceutical outlook pages. Syndicated sizing, not a Decision 12 diabetes SKU, switching or listing file. (accessed 17 October 2026).
    35. IMARC Group. UAE pharmaceutical market report pages. Syndicated market-size commentary that often occupies this query. (accessed 17 October 2026).
    36. IQVIA. UAE and Middle East pharmaceutical audit commentary. National audit context; not a substitute for EDE pricing-committee or payer-listing fieldwork. (accessed 17 October 2026).

    Explore related research

    For deeper regional insight, explore our healthcare market research framework and country coverage.

    Explore BioNixus capabilities & hubs

    Directory of every indexed marketing destination — GCC and MENA research pages, localized hubs, methodologies, pharmaceutical directories, reports, global websites, insights, case studies, methodology, and Arabic coverage. Prefer this index over generic “related” lists for full-site context.

    12 groups · 265 URLs

    Full structured sitemap
    Home & language hubsLocalized entry points for BioNixus.5
    Company, trust & methodologyAbout, contact, compliance, and how we work.28
    Core servicesQuantitative, qualitative, access, intelligence, trials, KOL.3
    Healthcare market research hubCountries, cities, therapy areas, and research modules.57
    GCC, MENA & specialty programsPillar landings, alternatives, and deep-dive reports.36
    Pharmaceutical company directoriesCountry-level industry snapshots.9
    Healthcare & devices market reportsGCC and country medical market briefs.1
    Blog & insightsEditorial briefs, guides, and regional analysis.80
    Case studiesSelected client evidence and programme outcomes.5
    Portfolio & conferenceStrategic portfolio deck and event pages.2
    Localized pagesMarket access, contacts, and market research by locale.6
    Additional pagesSupporting URLs and tooling.33

    FAQFrequently asked questions

    What is diabetes market research UAE after the 2026 price cuts?
    Commissioned work on the published list prices, analog risk, switching, pharmacy behaviour and payer listing. A prevalence slide is not that file.
    Did the Emirates Drug Establishment cut diabetes medicine prices in 2026?
    Gulf News reported that Decision 12 of 2026 cut prices of 168 products. The named diabetes examples were Amaryl 1 mg (AED 25 to AED 19), 2 mg (AED 39.50 to AED 32) and 3 mg (AED 57.50 to AED 47.50). Amaryl is glimepiride. GLP-1, SGLT2, DPP-4 and insulin cuts were not published as diabetes examples.
    How large were the published diabetes list cuts compared with other products?
    The press range for the 168 products was about 5% to nearly 60%. In the same report, Zocor 40 mg fell about 59.5% and Xalatan about 51.7%. Those are not diabetes cuts. Use the three Amaryl dirham pairs for the diabetes examples. Do not turn the headline range into a class cut.
    Is IDF’s 20.7% the right UAE diabetes figure for a 2026 forecast?
    It is one modelled 2024 figure for adults aged 20–79. The 2017–2018 survey reported 11.8%. The 2024–2025 survey reported elevated glucose of 12.5%. Do not average them. Do not apply any of them to 11.29 million residents as demand for Amaryl.
    Does a federal EDE price cut mean DHA or Thiqa will fund the product?
    No. Article 20 requires a Board-set price before marketing. Dubai Law 11 of 2013 and Abu Dhabi’s Thiqa rules still decide who pays. Circular 188/2025 is a Thiqa care pathway for adults 18 and older with two outpatient visits and HbA1c of 6.5% or higher. It is not a formulary listing.
    What should a brand team commission after Decision 12?
    A dose-level map of the named packs, physician diaries for new and continuing patients, pharmacy interviews on substitution, and separate DHA, Department of Health and insurer interviews. Decision 12 is one of 20 pricing decisions in the first half of 2026. Keep oral GLP-1 obesity research as a separate brief.
    Why commission BioNixus for diabetes market research UAE?
    Custom studies run from the Dubai field office, with a network of 82,000+ physicians globally and about 3,200 physicians in the Middle East, usually at $10k–$60k. Guaranteed in writing covers scope and sample. It does not cover what the interviews will find.

    Expert Consultation

    Planning diabetes pricing or post-cut listing research in the UAE?

    Tell us the diabetes decision you need to make. BioNixus scopes the study around that decision. Custom work is usually $10k–$60k.

    Talk to BioNixus
    M

    Research Author

    Martha DeVito

    Global Research Manager

    Related Articles

    Syndicated Saudi diabetes numbers size the category. They still miss which hospital is switching.
    Healthcare Market Research
    Saudi Arabia15 Nov 2026

    Syndicated Saudi diabetes numbers size the category. They still miss which hospital is switching.

    Syndicated Saudi diabetes reports size the category. They do not show which hospital is switching. Here is what primary research still has to answer.

    Read article
    ADCAN Pharma and M42 Want to Make the UAE an Oncology Supply Hub. The First Step Is a Pack, Not a Plant
    Healthcare Market Research
    UAE11 Nov 2026

    ADCAN Pharma and M42 Want to Make the UAE an Oncology Supply Hub. The First Step Is a Pack, Not a Plant

    ADCAN Pharma and M42 signed an MoU on UAE oncology manufacturing, an ADC registration and IROS clinical trials. What is confirmed and what to research.

    Read article
    The UAE Has Cleared Lilly's Foundayo Pill for Type 2 Diabetes. The Harder Questions Start Now
    Healthcare Market Research
    UAE10 Nov 2026

    The UAE Has Cleared Lilly's Foundayo Pill for Type 2 Diabetes. The Harder Questions Start Now

    The UAE approved Lilly's oral GLP-1 Foundayo for type 2 diabetes on 6 Nov 2026. What is confirmed, what is not, and what launch teams should research.

    Read article
    Novo Nordisk Gives Ozempic a Second Name, Plosbrio, and Hands It to Abbott in Asia Pacific
    Healthcare Market Research
    Singapore / Asia Pacific9 Nov 2026

    Novo Nordisk Gives Ozempic a Second Name, Plosbrio, and Hands It to Abbott in Asia Pacific

    Abbott will sell Plosbrio, Novo Nordisk's second semaglutide brand, in Singapore and Asia Pacific for type 2 diabetes. What is confirmed, what is not, and what it means for GLP-1 markets.

    Read article
    Avalon Pharma Signs for a Generic Mounjaro in Saudi Arabia Before It Can Launch One
    Healthcare Market Research
    Saudi Arabia5 Nov 2026

    Avalon Pharma Signs for a Generic Mounjaro in Saudi Arabia Before It Can Launch One

    Avalon Pharma licensed a generic Mounjaro KwikPen (tirzepatide) from OneSource for Saudi Arabia and MENA. What it means for GLP-1 and obesity teams.

    Read article

    Planning research in United Arab Emirates?

    Primary research, market access & HEOR. A 30-minute scoping call, then a costed proposal within 48 hours.

    What happens on the call

    • We pin down the decision your research has to support.
    • We check feasibility: respondent types, countries and timeline.
    • You receive a costed proposal within 48 hours of the call.